Concepedia

Laura Gibson

LG

Statistics

Publications

8

Citations

412

H-Index

8

Active since

2012

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

NYU Langone Health

Laura Gibson is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and checkpoint inhibitor therapy.

ORCID

Publications per year

2012–2024

8

Publications

8

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

Carminia Maria Della Corte, Triparna Sen, Carl M. Gay et al. · Journal of Thoracic Oncology · 2020 · 204 citations · Full text

, , +12

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

David H. Peng, B. Leticia Rodriguez, Lixia Diao et al. · Nature Communications · 2021 · 70 citations · Full text

, , +17

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer

Jessica Konen, B. Leticia Rodriguez, Jared J. Fradette et al. · Cancers · 2019 · 30 citations · Full text

, , +17

Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC

Jessica Konen, B. Leticia Rodriguez, Aparna Padhye et al. · Cancer Research · 2021 · 30 citations · Full text

, , +17

Testosterone enhances cardiomyogenesis in stem cells and recruits the androgen receptor to the MEF2C and HCN4 genes

Ashraf Al Madhoun, Anastassia Voronova, Tammy Ryan et al. · Journal of Molecular and Cellular Cardiology · 2013 · 28 citations

, , +16

1–5 of 8